China's pharmaceutical exports are steadily increasing

China's pharmaceutical exports are steadily increasing and the international competitive advantage is forming

Recently, the China Chamber of Commerce for the Import and Export of Healthcare products (hereinafter referred to as the Medical Insurance Chamber) released the export data of China's medicine trade in 2017. China's exports of healthcare products rose 9.44 percent to $60.799 billion in 2017, the biggest increase in nearly five years, reversing the decline of the previous year, according to statistics.

In China, the export volume of western medicine increased. In 2017, the export value of Chinese traditional medicine products was US $3.64 billion, an increase of 2.07% over the same period last year, while the export performance of western medicine products obviously rebounded, with an export value of US $35.456 billion, up 12.6% from the same period last year. 2%.

Meng Dongping, vice president of the Medicare Chamber of Commerce, said, "overall, the international pharmaceutical market demand will increase in 2017;" China's supply-side structural reform is beginning to show results, new momentum of development is being formed, China's pharmaceutical industry is forming a unique differentiated competitive advantage in the international market, the export volume of pharmaceutical products is increasing in volume and the export volume is steadily increasing. "

It has been learned that after years of accumulation, pharmaceutical enterprises in our country have climbed step by step from API, low-end preparations, high-end formulations and me too,me better,me best. Although there are still more low-level duplicates, the overall level of innovation is not so high. But the rise is inevitable.

Among them, innovative pharmaceutical enterprises have become the main force to stimulate the export of Chinese preparations, Hengrui Pharmaceutical, Qilu Pharmaceutical and other local pharmaceutical enterprises have successfully established themselves in the European and American markets and started to do something. "the fact that local pharmaceutical companies can gain a foothold in mainstream international markets, such as Europe and the United States, is not only conducive to the export of Chinese pharmaceutical products, but also gives people a glimpse of the momentum of the development of Chinese pharmaceuticals," Meng Dongping said.

In the case of Hengrui Medicine as an example, its R & D strength is strong, and it is rich in the research product line, and will enter the “Innovative drug + drug product outlet” period in the next three years, and the overseas market layout will be gradually improved and expanded.

R & D has a future. More and more companies are willing to invest in R & D. The author has learned that the two main lines of the upgrading of Chinese pharmaceutical industry have become increasingly clear, one is to comprehensively encourage innovation in the sense of policy, let the enterprises with innovative ability come out, kill out, and meet the unmet clinical needs of the public; One is to improve the standards of Chinese generic drug companies through consistency evaluation to ensure that people use more reliable generic drugs of better quality.

Nowadays, innovative drugs are rising in our country. There are more and more cases of foreign biopharmaceutical companies introducing overseas rights and interests of Chinese pharmaceutical companies to independently develop innovative drugs. The scale of the transaction is also getting higher and higher. In 2017, the transformation of pharmaceutical research and development achievements in China began to enter the harvest period, with 34 new pharmaceutical products newly obtained by enterprises applying for the (ANDA) number of concise new drugs in the United States (of which 8 are provisionally approved). 1.7 times the number approved last year. More and more enterprises go abroad to enter the US generic drug market.

Judging from the export data of China's pharmaceutical trade in 2017, although China's pharmaceutical industry is forming a unique differentiated competitive advantage in the international market, it has to be admitted that there are still some differences between China's pharmaceutical market and the international market. It is understood that China's local pharmaceutical R & D innovation level is still in the third echelon. In the annual R & D contribution, the products developed by Chinese enterprises are in the third echelon of global innovation contribution.

Now the whole Chinese medicine internationalization degree is also relatively low, the total export volume is relatively small. Statistics show that China's largest pharmaceutical companies now export less than 100 million a year. Fifty-four percent of exports go to Asia and Africa, while Europe and the United States account for only 29 percent. So to become an advanced manufacturing country, the pharmaceutical industry still has a long way to go.

In spite of this, I believe that with the introduction of national favorable policies, China's pharmaceutical industry will be vigorously developed. With the implementation of the "13th Five-Year Plan", China's pharmaceutical industry will be more orderly, high-tech content, environmental protection, resource savings. About, raise added value, extend downstream direction development, more advantageous to export structure continue to optimize and upgrade. It is expected that 2018 pharmaceutical foreign trade steady development of the fundamentals will continue to maintain.